Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Previously Treated AL Amyloidosis
NCT06649695Phase 2Active, not recruiting
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of teclistamab in amyloid light chain amyloidosis. Started Jul 2025; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06649695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649695.